TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nursing home operators say GLP-1 medications are appearing more often among new residents and are being used for conditions beyond diabetes and weight loss. Providers see potential benefits but must monitor nutrition and frailty, while coverage rules and facility costs remain concerns; a federal bridge program has been extended through 2027, and a more permanent plan has been delayed.
GLP-1 medications are becoming more common among nursing home residents, including people taking them for reasons beyond diabetes and weight loss, according to a Skilled Nursing News report. Operators say the drugs bring potential health benefits but also require closer clinical monitoring, staff education and decisions about who pays, particularly when coverage does not apply.
Lisa Chubb, chief nursing officer for New Jersey-based Venza Care, told Skilled Nursing News that about 30% to 40% of newly admitted residents at the operator are taking a GLP-1 medication. She said the share is higher in facilities with more short-stay residents. Chubb described use expanding toward cardiovascular prevention and other chronic, metabolic and organ-health concerns, alongside the more familiar uses for diabetes and weight loss.
Venza uses weekly “nutrition at risk” meetings to review residents’ risks, Chubb said. Its teams include registered dietitians, and electronic health record assessments prompt staff to document medication review and education and track weight loss. The clinical balance can be difficult: residents may choose to continue treatment, but weight loss can raise concerns about muscle weakness and frailty in an already vulnerable population.
Payment depends on the resident’s coverage and circumstances. Jessie McGill of the American Association for Post-Acute Care Nursing said a Medicare Part D bridge program covers certain GLP-1 prescriptions for weight loss, with a $50 monthly fee on top of Part D coverage. The program is limited to Wegovy, Zepbound and Foundeo, McGill said. It has been extended through 2027, while a more permanent proposal called BALANCE has been delayed without a new implementation date.
Care Plans Meet Medication Costs
More residents arriving on GLP-1s may change both care routines and facility budgets. Staff need to understand why a resident is taking the medication, monitor its effects and coordinate nutrition and weight tracking. Those demands add work across nursing, dietary and other clinical teams, rather than treating a prescription as a routine medication handoff.
Coverage gaps can also affect admission and operating decisions. McGill said a facility may be responsible for the drug’s cost for residents covered under Medicare Part A, depending on the circumstances. For operators, a medication that may support a resident’s health can also become a significant expense if it is not covered through an applicable program.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Levoit Core 400S-P Smart Air Purifier for Large Rooms
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Medicare Coverage and Facility Responsibilities
The bridge program’s rules leave some residents with costs even when a medication qualifies. McGill said residents who have both Medicare and Medicaid may still struggle to pay the monthly fee. The program also applies only to listed drugs and qualifying circumstances; the source report says eligibility includes tiers based on body mass index and other chronic conditions.
For residents with a GLP-1 prescription who are receiving care under Medicare Part A, McGill said the nursing home may have to account for the medication in its costs. She said expanding Medicare consolidated billing to include high-cost medications such as GLP-1s could be a next step for affordability. The report does not say that such an expansion has been adopted.
Jody O’Mara, chief nursing officer at Journey Skilled Nursing, said GLP-1 use could affect facility assessments, the types of residents operators accept and quality-assurance programs. She voiced support for the drugs’ potential value, while acknowledging the cost issue. Those comments describe an operator’s view, not a finding that treatment produces savings across nursing homes.
““We see a lot of our new admissions coming in with GLP-1s. Initially it was used solely for weight loss and diabetes, but now we’re seeing it trend in other directions as well.””
— Lisa Chubb, chief nursing officer for Venza Care
Coverage and Clinical Risks Still Vary
The report does not establish how widely GLP-1 use has spread across nursing homes nationally; the 30% to 40% figure comes from Venza Care’s newly admitted residents, not a national survey. It also does not provide comparative evidence on outcomes for nursing home residents taking the drugs.
Individual coverage and facility liability depend on the resident’s medication, eligibility and Medicare coverage. The report identifies potential adverse effects including nausea, vomiting, constipation and dehydration, but does not quantify how often they occur in this population. A permanent replacement for the bridge program has no announced implementation date.
Bridge Coverage Runs Through 2027
The Medicare bridge program is scheduled to continue through 2027. The report gives no date for a decision on BALANCE, the proposed permanent version, so residents and providers still face uncertainty about what coverage will follow. McGill identified congressional action to expand consolidated billing for high-cost medications as a possible route to reducing facility exposure, but no such change is confirmed.
In the meantime, nursing home teams will need to review residents’ prescriptions, eligibility and care needs individually. Operators may also adjust staff education, nutrition monitoring and budgeting as more residents arrive taking these medications.
Key Questions
How common are GLP-1 medications among nursing home admissions?
Venza Care’s Lisa Chubb said about 30% to 40% of newly admitted residents at her organization are taking them, with higher proportions in facilities serving more short-stay residents. The report does not give a national estimate.
Which medications qualify for the Medicare bridge program?
AAPACN’s Jessie McGill said the program covers Wegovy, Zepbound and Foundeo for eligible residents under specified conditions. The source report describes a $50 monthly fee in addition to Part D coverage.
How long is the bridge program set to continue?
The report says the program has been extended through 2027. A more permanent proposal, BALANCE, was delayed without a future implementation date.
Why do nursing homes monitor residents taking GLP-1 drugs?
Operators described monitoring weight and nutrition and educating staff. The report notes concerns about frailty and muscle weakness as well as possible side effects such as nausea, vomiting, constipation and dehydration.
Source: skillednursingnews.com
